Dual GLP-1/GIP Agonist · Metabolic Research · COA Verified
For research and laboratory use only. Not for human consumption. By purchasing, you confirm you are a qualified researcher.
For Research Purposes Only. Not approved for human consumption.
Tirzepatide is a synthetic dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly — the first-in-class twincretin peptide. In Phase 3 SURPASS trials, Tirzepatide achieved up to 22.5% weight loss, surpassing Semaglutide's results and establishing dual agonism as superior to single GLP-1 activation for metabolic endpoints. It serves as a critical comparator in research between single-mechanism (Semaglutide) and triple-mechanism (Retatrutide) approaches.
Q: What makes Tirzepatide unique?
A: First dual GIP/GLP-1 agonist ('twincretin') to reach Phase 3. Most metabolic peptides target one receptor. Tirzepatide targets two — establishing dual agonism as superior to single-mechanism approaches.
Q: What were the SURPASS trial results?
A: Tirzepatide achieved up to 22.5% weight loss in Phase 3 trials — exceeding Semaglutide's ~15% and setting the stage for triple agonists like Retatrutide to push further.
Q: How does Tirzepatide fit between Semaglutide and Retatrutide?
A: It is the middle tier: Semaglutide = single agonist (GLP-1 only); Tirzepatide = dual agonist (GLP-1 + GIP); Retatrutide = triple agonist (GLP-1 + GIP + Glucagon). Research often compares all three.
Related Research: Semaglutide Research Peptide | Retatrutide Triple Agonist | 2026 Metabolic Research Update | Cagrilintide Research Peptide | Retatrutide Complete Research Guide | Are Research Peptides Legal? | What Is a COA?
For laboratory research use only. Not for human consumption. Not evaluated by the FDA.
